Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.1750
+0.00150.86%
Post-market: 0.17980.0048+2.74%19:30 EDT
Volume:984.77K
Turnover:174.24K
Market Cap:5.33M
PE:-0.04
High:0.1818
Open:0.1772
Low:0.1730
Close:0.1735
52wk High:2.88
52wk Low:0.1659
Shares:30.44M
Float Shares:28.51M
Volume Ratio:0.60
T/O Rate:3.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.69
PE(LYR):-0.01

Loading ...

CPP Group to Delist from AIM and Raise £5m to Support Blink Parametric

TIPRANKS
·
Jun 25

Hargreave Hale AIM VCT Cuts Share Count with Targeted Buyback

TIPRANKS
·
Jun 25

Maven Renovar VCT wins full AGM backing for AIM Plus strategy shift

TIPRANKS
·
Jun 24

Gana Media Director Increases Stake with AIM Share Purchase

TIPRANKS
·
Jun 24

AIM Immunotech Completes Phase 2 Duripanc Trial Enrollment for Ampligen-imfinzi in Metastatic Pancreatic Cancer

Reuters
·
Jun 24

AIM Immunotech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

THOMSON REUTERS
·
Jun 24

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

GlobeNewswire
·
Jun 24

Blow to AIM as pawnbroker Ramsdens snapped up by US giant for £206m

cityam
·
Jun 23

M.P. Evans cuts share count with latest buyback on AIM

TIPRANKS
·
Jun 23

Vast Resources Extends Reverse Takeover Deadline as AIM Suspension Continues

TIPRANKS
·
Jun 23

Talon Resources Debuts on AIM as North American Gold Explorer with Eagle Lake Focus

TIPRANKS
·
Jun 23

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

GlobeNewswire
·
Jun 22

Restore plc Cancels 104,000 Shares After AIM Buyback

TIPRANKS
·
Jun 22

RentGuarantor Raises £1m in AIM Placing as Founder Trims Stake

TIPRANKS
·
Jun 20

B90 Chairman Increases Stake with AIM Share Purchase

TIPRANKS
·
Jun 19

Octopus AIM VCT 2 Cuts Share Count After Buyback, Updates Voting Rights

TIPRANKS
·
Jun 18

BRIEF-Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027

Reuters
·
Jun 18

AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient

MT Newswires Live
·
Jun 18

Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders

Reuters
·
Jun 18

AIM ImmunoTech completes first dosing for final patient in Phase 2 DURIPANC pancreatic cancer trial

Reuters
·
Jun 18